Eli Lilly and Company (NYSE:LLY) Shares Sold by InTrack Investment Management Inc

InTrack Investment Management Inc lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 34.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,950 shares of the company's stock after selling 1,566 shares during the quarter. Eli Lilly and Company accounts for approximately 2.2% of InTrack Investment Management Inc's portfolio, making the stock its 11th biggest position. InTrack Investment Management Inc's holdings in Eli Lilly and Company were worth $2,437,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at $43,000. FPC Investment Advisory Inc. boosted its position in shares of Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after acquiring an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $48,000. Compass Financial Services Inc acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $50,000. Finally, Capital A Wealth Management LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $63,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent analyst reports. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Stock Performance

LLY traded up $6.39 during trading on Thursday, reaching $815.00. The company's stock had a trading volume of 1,056,429 shares, compared to its average volume of 3,640,914. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a market capitalization of $772.40 billion, a price-to-earnings ratio of 69.60, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The company's fifty day moving average price is $771.74 and its 200-day moving average price is $800.91.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.58 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.